CTIS2023-507880-20-00招募中1 期
SYN510CT01
Eurofins Optimed0 个研究点目标入组 72 人开始时间: 2023年9月14日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 72
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 64（—）
- 性别
- All
入选标准
- 未提供
排除标准
- 未提供
研究者
相似试验
进行中（未招募）
1 期
A 52-week, Phase 1 Safety, Pharmacokinetic and Pharmacodynamic Trial of Siplizumab in Newly Diagnosed Adult Amyotrophic Lateral Sclerosis (ALS) Patients (AURORA)Amyotrophic Lateral SclerosisMedDRA version: 21.1Level: PTClassification code: 10002026Term: Amyotrophic lateral sclerosis Class: 100000004852CTIS2023-506174-12-00Itb-Med AB48
招募中
1 期
A phase I of TG6050 in the treatment of patients with metastatic lung canceron-small cell lung cancer (NSCLC)MedDRA version: 21.1Level: PTClassification code: 10059515Term: Non-small cell lung cancer metastatic Class: 100000004864CTIS2024-513093-22-00Transgene36
进行中（未招募）
1 期
A trial in healthy volunteers to study safety, tolerability, CS014-levels and effects in the body, after single and repeated doses of CS014, for the first time in humans.Cardiovascular diseaseCTIS2024-510878-24-00Cereno Scientific AB48
进行中（未招募）
1 期
This is clinical study to test, for the first time in people, the safety (anygood or bad effects), how long the drug can stay in the body and if it cancontrol the disease of people diagnosed with advanced cancer that has notresponded to treatment, has returned after it has been treated, or cannotbe treated by surgery, drugs, or any other known treatments.CTIS2023-509969-20-00Celgene Corp.133
招募中
1 期
A Phase 1, First-in-Human, Open-label Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of TT125-802 in Subjects with Advanced Solid TumorsCTIS2022-500849-24-00Tolremo Therapeutics AG25